1-44830004-A-G
Variant names:
Variant summary
Our verdict is Benign. The variant received -17 ACMG points: 0P and 17B. BP4_StrongBP6_Very_StrongBP7BS2
The NM_003738.5(PTCH2):c.840T>C(p.Ser280Ser) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00629 in 1,614,010 control chromosomes in the GnomAD database, including 56 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.0052 ( 4 hom., cov: 33)
Exomes 𝑓: 0.0064 ( 52 hom. )
Consequence
PTCH2
NM_003738.5 synonymous
NM_003738.5 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -3.32
Publications
3 publications found
Genes affected
PTCH2 (HGNC:9586): (patched 2) This gene encodes a transmembrane receptor of the patched gene family. The encoded protein may function as a tumor suppressor in the hedgehog signaling pathway. Alterations in this gene have been associated with nevoid basal cell carcinoma syndrome, basal cell carcinoma, medulloblastoma, and susceptibility to congenital macrostomia. Alternatively spliced transcript variants have been described.[provided by RefSeq, Oct 2009]
PTCH2 Gene-Disease associations (from GenCC):
- nevoid basal cell carcinoma syndromeInheritance: AD, Unknown Classification: MODERATE, SUPPORTIVE, LIMITED Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
- commissural facial cleftInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -17 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.95).
BP6
Variant 1-44830004-A-G is Benign according to our data. Variant chr1-44830004-A-G is described in ClinVar as Benign. ClinVar VariationId is 239562.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-3.32 with no splicing effect.
BS2
High AC in GnomAd4 at 788 AD,Unknown gene.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00518 AC: 788AN: 152082Hom.: 4 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
788
AN:
152082
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.00535 AC: 1343AN: 251018 AF XY: 0.00509 show subpopulations
GnomAD2 exomes
AF:
AC:
1343
AN:
251018
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00640 AC: 9362AN: 1461810Hom.: 52 Cov.: 32 AF XY: 0.00632 AC XY: 4595AN XY: 727198 show subpopulations
GnomAD4 exome
AF:
AC:
9362
AN:
1461810
Hom.:
Cov.:
32
AF XY:
AC XY:
4595
AN XY:
727198
show subpopulations
African (AFR)
AF:
AC:
18
AN:
33480
American (AMR)
AF:
AC:
105
AN:
44714
Ashkenazi Jewish (ASJ)
AF:
AC:
3
AN:
26134
East Asian (EAS)
AF:
AC:
527
AN:
39700
South Asian (SAS)
AF:
AC:
42
AN:
86236
European-Finnish (FIN)
AF:
AC:
983
AN:
53410
Middle Eastern (MID)
AF:
AC:
5
AN:
5766
European-Non Finnish (NFE)
AF:
AC:
7403
AN:
1111974
Other (OTH)
AF:
AC:
276
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.485
Heterozygous variant carriers
0
549
1098
1646
2195
2744
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
268
536
804
1072
1340
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.00518 AC: 788AN: 152200Hom.: 4 Cov.: 33 AF XY: 0.00547 AC XY: 407AN XY: 74438 show subpopulations
GnomAD4 genome
AF:
AC:
788
AN:
152200
Hom.:
Cov.:
33
AF XY:
AC XY:
407
AN XY:
74438
show subpopulations
African (AFR)
AF:
AC:
39
AN:
41518
American (AMR)
AF:
AC:
39
AN:
15290
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3468
East Asian (EAS)
AF:
AC:
35
AN:
5168
South Asian (SAS)
AF:
AC:
5
AN:
4824
European-Finnish (FIN)
AF:
AC:
182
AN:
10604
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
481
AN:
68010
Other (OTH)
AF:
AC:
7
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.505
Heterozygous variant carriers
0
41
81
122
162
203
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
21
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:4
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing
Sep 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
PTCH2: BP4, BP7, BS1, BS2
not specified Benign:1
Genome Diagnostics Laboratory, Amsterdam University Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing
Basal cell carcinoma, susceptibility to, 1 Benign:1
Jul 07, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
Gorlin syndrome Benign:1
Jan 30, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
Basal cell nevus syndrome 1 Benign:1
Feb 01, 2025
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.